Genmab A/S
NASDAQ:GMABBiotechnology
-$0.12 today
- Market cap
- $31.43B
- Beta
- 0.68
- P/E (TTM)
- 18.7
- EPS (TTM)
- $13.36
Volume 2.96M
Average 1.85M
GMAB Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Genmab A/SNASDAQ: GMAB
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables rises 28.3% from a year ago
Net receivables stood at $1.28B at the end of Q2 FY2026, up 28.3% from a year earlier and up 24.2% from the prior quarter. Over 3 fiscal years it compounded at -41.4% a year.
Context
- Net receivables amounted to 10.2% of total assets at the end of Q2 FY2026, down 5.2 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +28.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 1.15B USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.15B | — |
| FY2024 | 2024-12-31 | 6.69B | +35.3% |
| FY2023 | 2023-12-31 | 4.95B | -13.4% |
| FY2022 | 2022-12-31 | 5.71B | +69.6% |
| FY2021 | 2021-12-31 | 3.37B | — |
Net Receivables vs competitors
How GMAB compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +28.3% is the 4th highest of 11, against a peer median of +3.5%.
- Net receivables amounts to 10.2% of total assets for GMAB, versus a peer median of 7.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.28B USD | +28.3% | -41.4% | 10.2% | |
| Jun 2026 | $1.13B USD | +33.5% | +16.7% | 14.3% | |
| Jul 2026 | $334.61M USD | +14.5% | +10.1% | 13.4% | |
| Jun 2026 | €245.1M EUR | -83.1% | -48.4% | 1.2% | |
| Sep 2026 | $218.9M USD | +8.1% | +77.8% | 13.0% | |
| Sep 2026 | $106.99M USD | +60.3% | — | 10.8% | |
| Jun 2026 | $36M USD | +80.0% | -28.1% | 3.9% | |
| Mar 2026 | $31.05M USD | -2.3% | -26.4% | 10.7% | |
| Mar 2026 | $10.43M USD | -1.1% | -38.0% | 4.8% | |
| Mar 2026 | $2.34M USD | -25.7% | -2.5% | 1.6% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding GMAB) | — | +3.5% | -14.4% | 7.7% | |
Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · DKK | FY2022 Dec 2022 · DKK | FY2023 Dec 2023 · DKK | FY2024 Dec 2024 · DKK | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.96B | 9.89B | 14.87B | 9.86B | 1.71B |
| Short-term Investments | 10.38B | 12.43B | 13.27B | 11.24B | 0 |
| Net Receivables | 3.37B | 5.71B | 4.95B | 6.69B | 1.15B |
| Inventory | 0 | 0 | 57M | 62M | 17.96M |
| Other Current Assets | 31M | 182M | 0 | 0 | 3 |
| Total Current Assets | 22.74B | 28.22B | 33.14B | 27.85B | 2.88B |
| Property, Plant & Equipment (Net) | 975M | 1.32B | 1.64B | 263.83M | 279.36M |
| Goodwill | 0 | 0 | 0 | 2.54B | 354.19M |
| Intangible Assets | 254M | 146M | 101M | 12.34B | 9.1B |
| Long-term Investments | 371M | 133M | 134M | 228M | 58.87M |
| Tax Assets | 0 | 0 | 212M | 126.68M | 170.61M |
| Other Non-current Assets | 291M | 300M | 62M | 2.46B | 4 |
| Total Non-current Assets | 1.89B | 1.9B | 2.15B | 17.96B | 9.97B |
| Total Assets | 24.63B | 30.12B | 35.29B | 45.81B | 12.84B |
| Account Payables | 350M | 0 | 0 | 0 | 1.07B |
| Short-term Debt | 0 | 0 | 0 | 0 | 273M |
| Tax Payables | 0 | 0 | 54M | 1.71B | 0 |
| Deferred Revenue | 0 | 0 | 33M | 24M | 23.95M |
| Other Current Liabilities | 860M | 1.75B | 0 | 0 | (663.92K) |
| Total Current Liabilities | 1.57B | 1.82B | 2.48B | 5.31B | 1.42B |
| Long-term Debt | 0 | 0 | 0 | 0 | 5B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 2.36B | 363.17M |
| Deferred Revenue (Non-current) | 0 | 0 | 480M | 480M | 94.78M |
| Other Non-current Liabilities | 500M | 491M | 35M | 30M | 5M |
| Total Non-current Liabilities | 863M | 1.01B | 1.2B | 3.81B | 5.59B |
| Total Liabilities | 2.43B | 2.84B | 3.68B | 9.11B | 7.01B |
| Common Stock | 66M | 66M | 66M | 66M | 9.98M |
| Retained Earnings | 10.02B | 14.81B | 19.02B | 23.55B | 4.09B |
| Accumulated OCI | 81M | 98M | 60M | 490M | (180.59M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 22.2B | 27.28B | 31.61B | 36.7B | 5.83B |
| Total Debt | 425M | 597M | 770M | 1.03B | 5.43B |
| Net Debt | (8.53B) | (9.3B) | (14.1B) | (8.83B) | 3.71B |
Genmab A/S
NASDAQ:GMAB
Intrinsic Alpha fair value
Locked
Current Price
$50.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.